THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Herantis Pharma Plc ("Herantis" or the "Company"), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson's disease, announced on 5 December 2023 the result of the offering of new shares in a directed share issue to institutional and other qualified investors (the "Directed Issue"). In the Directed Issue, the Company issued a total of 3,219,139 new shares, of which the remaining 1,071,429 new shares have today been registered with the trade register maintained by the Finnish Patent and Registration Office (the "New Shares"). With the registration of the New Shares, all shares issued in the Directed Issue have now been registered with the trade register.

Following the registration of the New Shares, the total number of registered shares in the Company is 20,160,733. The New Shares will be issued in the book-entry system (ISIN code FI4000087861) on or about 14 December 2023. After this, and registration on the investors' book-entry accounts, the New Shares will confer shareholder rights in the Company. The New Shares are expected to be ready for delivery to the investors through Euroclear Finland Ltd on or about 14 December 2023.

Trading in the New Shares is expected to commence on Nasdaq First North Growth Market Finland on or about 14 December 2023.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel.: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Us

About Herantis Pharma Plc

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com